Last reviewed · How we verify
Approved Anti-PD-1 Inhibitor — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Approved Anti-PD-1 Inhibitor (Approved Anti-PD-1 Inhibitor) — Dynavax Technologies Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Approved Anti-PD-1 Inhibitor TARGET | Approved Anti-PD-1 Inhibitor | Dynavax Technologies Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Approved Anti-PD-1 Inhibitor CI watch — RSS
- Approved Anti-PD-1 Inhibitor CI watch — Atom
- Approved Anti-PD-1 Inhibitor CI watch — JSON
- Approved Anti-PD-1 Inhibitor alone — RSS
Cite this brief
Drug Landscape (2026). Approved Anti-PD-1 Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/approved-anti-pd-1-inhibitor. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab